The use of latency reversing agents is useful for reducing the HIV reservoir, but their effect on infected cells isolated from untreated people with HIV is still unknown.
At this week’s ACS meeting in New Orleans, Fimbrion Therapeutics Inc. presented the rational design of a different series of small-molecule biaryl O- and C-linked mannoside-based inhibitors of the virulence factor FimH, as potential agents for the treatment of urinary tract infections (UTIs).
Researchers from the University of Stellenbosch in South Africa are seeking protection for a simple and user-friendly point-of-care device for diagnosing tuberculosis. Their electrochemical lateral flow device merges lateral flow device technology and electrochemical device technology by using porous electrodes that are capable of transporting electrolytic liquid and fluid sample.
Retinoids are derivatives of vitamin A that target the retinoid receptors and induce antiproliferative effects and cell death. George Washington University has tested a series of different retinoids, including alitretinoin, tazarotene and AM-80, also known as tamibarotene, for their efficacy against HIV-infected CD4+ T cells regarding their ability to enhance the cytotoxic effect of NK cells.
In a recent study led by Soman Abraham from Duke University, investigators observed that an increase in nociceptive sensory nerves in urinary tract biopsies from patients with recurrent urinary tract infections (rUTIs) was linked to elevated nerve growth factor (NGF) from monocytes and mast cells. This overgrowth of nerve cells appeared to cause lingering symptoms after rUTIs.
Researchers from Henan University and affiliated organizations disclosed the discovery of new bis-substituted aromatic amides as potent antibiotic agents.
One topic at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held in Denver this month was that resistance to antiretroviral therapy (ART) has become a public health problem for people living with HIV. Without a vaccine or a cure, these patients depend on treatments that suppress viremia by preventing the virus from replicating. They are lifelong treatments and, until new advances succeed in eradicating the virus from reservoirs, the only option available.
Several presentations at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held in Denver from March 3 to 6, 2024, focused on childhood HIV and highlighted the lack of pediatric data. The epicenter of this pandemic in the youngest is in the southern region of the African continent. However, there are few studies for children with HIV, mostly for the northern hemisphere.
Enanta Pharmaceuticals Inc. has disclosed new fused heterobicyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.
Overall, the story of HIV is one of astounding success. But to declare victory, it will be necessary to develop a vaccine. The opening session of the 31st Conference on Retroviruses and Opportunistic Infections (CROI) 2024 looked back to the failures but also the advances in research, all the steps that over the years brought the basic science knowledge that could bring an HIV vaccine in the future. This year, the former director of the Viral Pathogenesis Laboratory at the NIAID Vaccine Research Center, Barney Graham, was named for the Bernard Field Lecture, where he presented “Modern vaccinology: a legacy of HIV research.”
RSS
